

WHAT IS CLAIMED IS:

1. An isolated nucleic acid having at least 80% nucleic acid sequence identity to a nucleotide sequence that encodes an amino acid sequence selected from the group consisting of the amino acid sequence shown in Figure 2 (SEQ ID NO:4), Figure 4 (SEQ ID NO:6), Figure 6 (SEQ ID NO:8), Figure 8 (SEQ ID NO:10), Figure 10 (SEQ ID NO:12), Figure 12 (SEQ ID NO:17), Figure 14 (SEQ ID NO:22), Figure 16 (SEQ ID NO:24), Figure 18 (SEQ ID NO:29), Figure 20 (SEQ ID NO:31), Figure 22 (SEQ ID NO:33), Figure 24 (SEQ ID NO:41), Figure 26 (SEQ ID NO:43), Figure 28 (SEQ ID NO:50), Figure 30 (SEQ ID NO:52), Figure 32 (SEQ ID NO:54), Figure 34 (SEQ ID NO:56), Figure 36 (SEQ ID NO:58), Figure 38 (SEQ ID NO:63), Figure 40 (SEQ ID NO:68), Figure 42 (SEQ ID NO:70), Figure 44 (SEQ ID NO:72), Figure 46 (SEQ ID NO:77), Figure 48 (SEQ ID NO:79), Figure 50 (SEQ ID NO:84), Figure 52 (SEQ ID NO:86), Figure 54 (SEQ ID NO:88), Figure 56 (SEQ ID NO:95), Figure 58 (SEQ ID NO:100), Figure 60 (SEQ ID NO:102), Figure 62 (SEQ ID NO:104), Figure 64 (SEQ ID NO:111), Figure 66 (SEQ ID NO:116), Figure 68 (SEQ ID NO:118), Figure 70 (SEQ ID NO:123), Figure 72 (SEQ ID NO:128), Figure 74 (SEQ ID NO:130), Figure 76 (SEQ ID NO:132), Figure 78 (SEQ ID NO:134), Figure 80 (SEQ ID NO:136), Figure 82 (SEQ ID NO:138), Figure 84 (SEQ ID NO:140), Figure 86 (SEQ ID NO:142), Figure 88 (SEQ ID NO:144), Figure 90 (SEQ ID NO:146), Figure 92 (SEQ ID NO:148), Figure 94 (SEQ ID NO:153), Figure 96 (SEQ ID NO:158), Figure 98 (SEQ ID NO:160), Figure 100 (SEQ ID NO:162), Figure 102 (SEQ ID NO:170), Figure 104 (SEQ ID NO:180), Figure 106 (SEQ ID NO:189), Figure 108 (SEQ ID NO:194), Figure 110 (SEQ ID NO:196), Figure 112 (SEQ ID NO:198), Figure 114 (SEQ ID NO:203), Figure 116 (SEQ ID NO:210), Figure 118 (SEQ ID NO:212), Figure 120 (SEQ ID NO:214), Figure 122 (SEQ ID NO:216), Figure 124 (SEQ ID NO:218), Figure 126 (SEQ ID NO:220), Figure 128 (SEQ ID NO:225), Figure 130 (SEQ ID NO:227), Figure 132 (SEQ ID NO:229), Figure 134 (SEQ ID NO:234), Figure 136 (SEQ ID NO:236), Figure 138 (SEQ ID NO:243), Figure 140 (SEQ ID NO:248), Figure 142 (SEQ ID NO:253), Figure 144 (SEQ ID NO:260), Figure 146 (SEQ ID NO:265), Figure 148 (SEQ ID NO:267), Figure 150 (SEQ ID NO:269), Figure 152 (SEQ ID NO:271), Figure 154 (SEQ ID NO:273), Figure 156 (SEQ ID NO:275), Figure 158 (SEQ ID NO:277), Figure 160 (SEQ ID NO:282), Figure 162 (SEQ ID NO:287), Figure 164 (SEQ ID NO:292), Figure 166 (SEQ ID NO:297), Figure 168 (SEQ ID NO:302), Figure 170 (SEQ ID NO:304), Figure 172 (SEQ ID NO:306), Figure 174 (SEQ ID NO:308), Figure 176 (SEQ ID NO:310), Figure 178 (SEQ ID NO:315), Figure 180 (SEQ ID NO:317), Figure 182 (SEQ ID NO:322), Figure 184 (SEQ ID NO:324), Figure 186 (SEQ ID NO:326), Figure 188 (SEQ ID NO:328), Figure 190 (SEQ ID NO:330), Figure 192 (SEQ ID NO:332), Figure 194 (SEQ ID NO:334), Figure 196 (SEQ ID NO:336), Figure 198 (SEQ ID NO:338), Figure 200 (SEQ ID NO:340), Figure 202 (SEQ ID NO:347), Figure 204 (SEQ ID NO:352), Figure 206 (SEQ ID NO:354), Figure 208 (SEQ ID NO:356), Figure 210 (SEQ ID NO:358), Figure 212 (SEQ ID NO:364), Figure 214 (SEQ ID NO:366), Figure 216 (SEQ ID NO:372), Figure 218 (SEQ ID NO:374), Figure 220 (SEQ ID NO:376), Figure 222 (SEQ ID NO:378), Figure 224 (SEQ ID NO:383), Figure 226 (SEQ ID NO:385), Figure 228 (SEQ ID NO:390), Figure 230 (SEQ ID NO:395), Figure 232 (SEQ ID NO:397), Figure 234 (SEQ ID NO:402), Figure 236 (SEQ ID NO:406), Figure 238 (SEQ ID NO:410), Figure 240 (SEQ ID NO:415), Figure 242 (SEQ ID NO:423), Figure 244 (SEQ ID NO:429) and Figure 246 (SEQ ID NO:431).
2. The nucleic acid of Claim 1, wherein said nucleotide sequence comprises a nucleotide sequence

selected from the group consisting of the sequence shown in Figure 1 (SEQ ID NO:3), Figure 3 (SEQ ID NO:5), Figure 5 (SEQ ID NO:7), Figure 7 (SEQ ID NO:9), Figure 9 (SEQ ID NO:11), Figure 11 (SEQ ID NO:16), Figure 13 (SEQ ID NO:21), Figure 15 (SEQ ID NO:23), Figure 17 (SEQ ID NO:28), Figure 19 (SEQ ID NO:30), Figure 21 (SEQ ID NO:32), Figure 23 (SEQ ID NO:40), Figure 25 (SEQ ID NO:42), Figure 27 (SEQ ID NO:49), Figure 29 (SEQ ID NO:51), Figure 31 (SEQ ID NO:53), Figure 33 (SEQ ID NO:55), Figure 35 (SEQ ID NO:57), Figure 37 (SEQ ID NO:62), Figure 39 (SEQ ID NO:67), Figure 41 (SEQ ID NO:69), Figure 43 (SEQ ID NO:71), Figure 45 (SEQ ID NO:76), Figure 47 (SEQ ID NO:78), Figure 49 (SEQ ID NO:83), Figure 51 (SEQ ID NO:85), Figure 53 (SEQ ID NO:87), Figure 55 (SEQ ID NO:94), Figure 57 (SEQ ID NO:99), Figure 59 (SEQ ID NO:101), Figure 61 (SEQ ID NO:103), Figure 63 (SEQ ID NO:110), Figure 65 (SEQ ID NO:115), Figure 67 (SEQ ID NO:117), Figure 69 (SEQ ID NO:122), Figure 71 (SEQ ID NO:127), Figure 73 (SEQ ID NO:129), Figure 75 (SEQ ID NO:131), Figure 77 (SEQ ID NO:133), Figure 79 (SEQ ID NO:135), Figure 81 (SEQ ID NO:137), Figure 83 (SEQ ID NO:139), Figure 85 (SEQ ID NO:141), Figure 87 (SEQ ID NO:143), Figure 89 (SEQ ID NO:145), Figure 91 (SEQ ID NO:147), Figure 93 (SEQ ID NO:152), Figure 95 (SEQ ID NO:157), Figure 97 (SEQ ID NO:159), Figure 99 (SEQ ID NO:161), Figure 101 (SEQ ID NO:169), Figure 103 (SEQ ID NO:179), Figure 105 (SEQ ID NO:188), Figure 107 (SEQ ID NO:193), Figure 109 (SEQ ID NO:195), Figure 111 (SEQ ID NO:197), Figure 113 (SEQ ID NO:202), Figure 115 (SEQ ID NO:209), Figure 117 (SEQ ID NO:211), Figure 119 (SEQ ID NO:213), Figure 121 (SEQ ID NO:215), Figure 123 (SEQ ID NO:217), Figure 125 (SEQ ID NO:219), Figure 127 (SEQ ID NO:224), Figure 129 (SEQ ID NO:226), Figure 131 (SEQ ID NO:228), Figure 133 (SEQ ID NO:233), Figure 135 (SEQ ID NO:235), Figure 137 (SEQ ID NO:242), Figure 139 (SEQ ID NO:247), Figure 141 (SEQ ID NO:252), Figure 143 (SEQ ID NO:259), Figure 145 (SEQ ID NO:264), Figure 147 (SEQ ID NO:266), Figure 149 (SEQ ID NO:268), Figure 151 (SEQ ID NO:270), Figure 153 (SEQ ID NO:272), Figure 155 (SEQ ID NO:274), Figure 157 (SEQ ID NO:276), Figure 159 (SEQ ID NO:281), Figure 161 (SEQ ID NO:286), Figure 163 (SEQ ID NO:291), Figure 165 (SEQ ID NO:296), Figure 167 (SEQ ID NO:301), Figure 169 (SEQ ID NO:303), Figure 171 (SEQ ID NO:305), Figure 173 (SEQ ID NO:307), Figure 175 (SEQ ID NO:309), Figure 177 (SEQ ID NO:314), Figure 179 (SEQ ID NO:316), Figure 181 (SEQ ID NO:321), Figure 183 (SEQ ID NO:323), Figure 185 (SEQ ID NO:325), Figure 187 (SEQ ID NO:327), Figure 189 (SEQ ID NO:329), Figure 191 (SEQ ID NO:331), Figure 193 (SEQ ID NO:333), Figure 195 (SEQ ID NO:335), Figure 197 (SEQ ID NO:337), Figure 199 (SEQ ID NO:339), Figure 201 (SEQ ID NO:346), Figure 203 (SEQ ID NO:351), Figure 205 (SEQ ID NO:353), Figure 207 (SEQ ID NO:355), Figure 209 (SEQ ID NO:357), Figure 211 (SEQ ID NO:363), Figure 213 (SEQ ID NO:365), Figure 215 (SEQ ID NO:371), Figure 217 (SEQ ID NO:373), Figure 219 (SEQ ID NO:375), Figure 221 (SEQ ID NO:377), Figure 223 (SEQ ID NO:382), Figure 225 (SEQ ID NO:384), Figure 227 (SEQ ID NO:389), Figure 229 (SEQ ID NO:394), Figure 231 (SEQ ID NO:396), Figure 233 (SEQ ID NO:401), Figure 235 (SEQ ID NO:405), Figure 237 (SEQ ID NO:409), Figure 239 (SEQ ID NO:414), Figure 241 (SEQ ID NO:422), Figure 242 (SEQ ID NO:428) and Figure 245 (SEQ ID NO:430).

3. The nucleic acid of Claim 1, wherein said nucleotide sequence comprises a nucleotide sequence selected from the group consisting of the full-length coding sequence of the sequence shown in Figure 1 (SEQ

ID NO:3), Figure 3 (SEQ ID NO:5), Figure 5 (SEQ ID NO:7), Figure 7 (SEQ ID NO:9), Figure 9 (SEQ ID NO:11), Figure 11 (SEQ ID NO:16), Figure 13 (SEQ ID NO:21), Figure 15 (SEQ ID NO:23), Figure 17 (SEQ ID NO:28), Figure 19 (SEQ ID NO:30), Figure 21 (SEQ ID NO:32), Figure 23 (SEQ ID NO:40), Figure 25 (SEQ ID NO:42), Figure 27 (SEQ ID NO:49), Figure 29 (SEQ ID NO:51), Figure 31 (SEQ ID NO:53), Figure 33 (SEQ ID NO:55), Figure 35 (SEQ ID NO:57), Figure 37 (SEQ ID NO:62), Figure 39 (SEQ ID NO:67),
 5 Figure 41 (SEQ ID NO:69), Figure 43 (SEQ ID NO:71), Figure 45 (SEQ ID NO:76), Figure 47 (SEQ ID NO:78), Figure 49 (SEQ ID NO:83), Figure 51 (SEQ ID NO:85), Figure 53 (SEQ ID NO:87), Figure 55 (SEQ ID NO:94), Figure 57 (SEQ ID NO:99), Figure 59 (SEQ ID NO:101), Figure 61 (SEQ ID NO:103), Figure 63 (SEQ ID NO:110), Figure 65 (SEQ ID NO:115), Figure 67 (SEQ ID NO:117), Figure 69 (SEQ ID NO:122), Figure 71 (SEQ ID NO:127), Figure 73 (SEQ ID NO:129), Figure 75 (SEQ ID NO:131), Figure 77 (SEQ ID NO:133), Figure 79 (SEQ ID NO:135), Figure 81 (SEQ ID NO:137), Figure 83 (SEQ ID NO:139), Figure 85 (SEQ ID NO:141), Figure 87 (SEQ ID NO:143), Figure 89 (SEQ ID NO:145), Figure 91 (SEQ ID NO:147), Figure 93 (SEQ ID NO:152), Figure 95 (SEQ ID NO:157), Figure 97 (SEQ ID NO:159), Figure 99 (SEQ ID NO:161), Figure 101 (SEQ ID NO:169), Figure 103 (SEQ ID NO:179), Figure 105 (SEQ ID NO:188), Figure 107 (SEQ ID NO:193), Figure 109 (SEQ ID NO:195), Figure 111 (SEQ ID NO:197), Figure 113 (SEQ ID NO:202), Figure 115 (SEQ ID NO:209), Figure 117 (SEQ ID NO:211), Figure 119 (SEQ ID NO:213), Figure 121 (SEQ ID NO:215), Figure 123 (SEQ ID NO:217), Figure 125 (SEQ ID NO:219), Figure 127 (SEQ ID NO:224), Figure 129 (SEQ ID NO:226), Figure 131 (SEQ ID NO:228), Figure 133 (SEQ ID NO:233), Figure 135 (SEQ ID NO:235), Figure 137 (SEQ ID NO:242), Figure 139 (SEQ ID NO:247), Figure 141 (SEQ ID NO:252), Figure 143 (SEQ ID NO:259), Figure 145 (SEQ ID NO:264), Figure 147 (SEQ ID NO:266), Figure 149 (SEQ ID NO:268), Figure 151 (SEQ ID NO:270), Figure 153 (SEQ ID NO:272), Figure 155 (SEQ ID NO:274), Figure 157 (SEQ ID NO:276), Figure 159 (SEQ ID NO:281), Figure 161 (SEQ ID NO:286), Figure 163 (SEQ ID NO:291), Figure 165 (SEQ ID NO:296), Figure 167 (SEQ ID NO:301), Figure 169 (SEQ ID NO:303), Figure 171 (SEQ ID NO:305), Figure 173 (SEQ ID NO:307), Figure 175 (SEQ ID NO:309), Figure 177 (SEQ ID NO:314), Figure 179 (SEQ ID NO:316), Figure 181 (SEQ ID NO:321), Figure 183 (SEQ ID NO:323), Figure 185 (SEQ ID NO:325), Figure 187 (SEQ ID NO:327), Figure 189 (SEQ ID NO:329), Figure 191 (SEQ ID NO:331), Figure 193 (SEQ ID NO:333), Figure 195 (SEQ ID NO:335), Figure 197 (SEQ ID NO:337), Figure 199 (SEQ ID NO:339), Figure 201 (SEQ ID NO:346), Figure 203 (SEQ ID NO:351), Figure 205 (SEQ ID NO:353), Figure 207 (SEQ ID NO:355), Figure 209 (SEQ ID NO:357), Figure 211 (SEQ ID NO:363), Figure 213 (SEQ ID NO:365), Figure 215 (SEQ ID NO:371), Figure 217 (SEQ ID NO:373), Figure 219 (SEQ ID NO:375), Figure 221 (SEQ ID NO:377), Figure 223 (SEQ ID NO:382), Figure 225 (SEQ ID NO:384), Figure 227 (SEQ ID NO:389), Figure 229 (SEQ ID NO:394), Figure 231 (SEQ ID NO:396), Figure 233 (SEQ ID NO:401), Figure 235 (SEQ ID NO:405), Figure 237 (SEQ ID NO:409), Figure 239 (SEQ ID NO:414), Figure 241 (SEQ ID NO:422), Figure 242 (SEQ ID NO:428) and Figure 245 (SEQ ID NO:430).

35 4. Isolated nucleic acid which comprises the full-length coding sequence of the DNA deposited under any ATCC accession number shown in Table 12.

5. A vector comprising the nucleic acid of Claim 1.

6. The vector of Claim 5 operably linked to control sequences recognized by a host cell transformed with the vector.

7. A host cell comprising the vector of Claim 5.

5 8. The host cell of Claim 7 wherein said cell is a CHO cell.

9. The host cell of Claim 7 wherein said cell is an *E. coli*.

10. The host cell of Claim 7 wherein said cell is a yeast cell.

10

11. A process for producing a PRO polypeptides comprising culturing the host cell of Claim 7 under conditions suitable for expression of said PRO polypeptide and recovering said PRO polypeptide from the cell culture.

15

12. Isolated PRO polypeptide having at least 80% amino acid sequence identity to an amino acid sequence selected from the group consisting of the amino acid sequence shown in Figure 2 (SEQ ID NO:4), Figure 4 (SEQ ID NO:6), Figure 6 (SEQ ID NO:8), Figure 8 (SEQ ID NO:10), Figure 10 (SEQ ID NO:12), Figure 12 (SEQ ID NO:17), Figure 14 (SEQ ID NO:22), Figure 16 (SEQ ID NO:24), Figure 18 (SEQ ID NO:29), Figure 20 (SEQ ID NO:31), Figure 22 (SEQ ID NO:33), Figure 24 (SEQ ID NO:41), Figure 26 (SEQ ID NO:43), Figure 28 (SEQ ID NO:50), Figure 30 (SEQ ID NO:52), Figure 32 (SEQ ID NO:54), Figure 34 (SEQ ID NO:56), Figure 36 (SEQ ID NO:58), Figure 38 (SEQ ID NO:63), Figure 40 (SEQ ID NO:68), Figure 42 (SEQ ID NO:70), Figure 44 (SEQ ID NO:72), Figure 46 (SEQ ID NO:77), Figure 48 (SEQ ID NO:79), Figure 50 (SEQ ID NO:84), Figure 52 (SEQ ID NO:86), Figure 54 (SEQ ID NO:88), Figure 56 (SEQ ID NO:95), Figure 58 (SEQ ID NO:100), Figure 60 (SEQ ID NO:102), Figure 62 (SEQ ID NO:104), Figure 64 (SEQ ID NO:111), Figure 66 (SEQ ID NO:116), Figure 68 (SEQ ID NO:118), Figure 70 (SEQ ID NO:123), Figure 72 (SEQ ID NO:128), Figure 74 (SEQ ID NO:130), Figure 76 (SEQ ID NO:132), Figure 78 (SEQ ID NO:134), Figure 80 (SEQ ID NO:136), Figure 82 (SEQ ID NO:138), Figure 84 (SEQ ID NO:140), Figure 86 (SEQ ID NO:142), Figure 88 (SEQ ID NO:144), Figure 90 (SEQ ID NO:146), Figure 92 (SEQ ID NO:148), Figure 94 (SEQ ID NO:153), Figure 96 (SEQ ID NO:158), Figure 98 (SEQ ID NO:160), Figure 100 (SEQ ID NO:162), Figure 102 (SEQ ID NO:170), Figure 104 (SEQ ID NO:180), Figure 106 (SEQ ID NO:189), Figure 108 (SEQ ID NO:194), Figure 110 (SEQ ID NO:196), Figure 112 (SEQ ID NO:198), Figure 114 (SEQ ID NO:203), Figure 116 (SEQ ID NO:210), Figure 118 (SEQ ID NO:212), Figure 120 (SEQ ID NO:214), Figure 122 (SEQ ID NO:216), Figure 124 (SEQ ID NO:218), Figure 126 (SEQ ID NO:220), Figure 128 (SEQ ID NO:225), Figure 130 (SEQ ID NO:227), Figure 132 (SEQ ID NO:229), Figure 134 (SEQ ID NO:234), Figure 136 (SEQ ID NO:236), Figure 138 (SEQ ID NO:243), Figure 140 (SEQ ID NO:248), Figure 142 (SEQ ID NO:253), Figure 144 (SEQ ID NO:260), Figure 146 (SEQ ID NO:265), Figure 148 (SEQ ID NO:267), Figure 150 (SEQ ID NO:269), Figure 152 (SEQ ID NO:271), Figure 154 (SEQ ID NO:273), Figure 156 (SEQ ID NO:275), Figure 158 (SEQ ID NO:277), Figure 160 (SEQ ID NO:282), Figure 162 (SEQ ID NO:287), Figure 164 (SEQ ID NO:292), Figure 166 (SEQ ID NO:297), Figure 168 (SEQ ID NO:302), Figure 170 (SEQ ID

NO:304), Figure 172 (SEQ ID NO:306), Figure 174 (SEQ ID NO:308), Figure 176 (SEQ ID NO:310), Figure 178 (SEQ ID NO:315), Figure 180 (SEQ ID NO:317), Figure 182 (SEQ ID NO:322), Figure 184 (SEQ ID NO:324), Figure 186 (SEQ ID NO:326), Figure 188 (SEQ ID NO:328), Figure 190 (SEQ ID NO:330), Figure 192 (SEQ ID NO:332), Figure 194 (SEQ ID NO:334), Figure 196 (SEQ ID NO:336), Figure 198 (SEQ ID NO:338), Figure 200 (SEQ ID NO:340), Figure 202 (SEQ ID NO:347), Figure 204 (SEQ ID NO:352), Figure 206 (SEQ ID NO:354), Figure 208 (SEQ ID NO:356), Figure 210 (SEQ ID NO:358), Figure 212 (SEQ ID NO:364), Figure 214 (SEQ ID NO:366), Figure 216 (SEQ ID NO:372), Figure 218 (SEQ ID NO:374), Figure 220 (SEQ ID NO:376), Figure 222 (SEQ ID NO:378), Figure 224 (SEQ ID NO:383), Figure 226 (SEQ ID NO:385), Figure 228 (SEQ ID NO:390), Figure 230 (SEQ ID NO:395), Figure 232 (SEQ ID NO:397), Figure 234 (SEQ ID NO:402), Figure 236 (SEQ ID NO:406), Figure 238 (SEQ ID NO:410), Figure 240 (SEQ ID NO:415), Figure 242 (SEQ ID NO:423), Figure 244 (SEQ ID NO:429) and Figure 246 (SEQ ID NO:431).

13. Isolated PRO polypeptide having at least 80% sequence identity to the amino acid sequence encoded by a nucleic acid molecule deposited under any ATCC accession number shown in Table 12.

14. A chimeric molecule comprising a polypeptide according to Claim 12 fused to a heterologous amino acid sequence.

15. The chimeric molecule of Claim 14 wherein said heterologous amino acid sequence is an epitope tag sequence.

16. The chimeric molecule of Claim 14 wherein said heterologous amino acid sequence is a Fc region of an immunoglobulin.

17. An antibody which specifically binds to a PRO polypeptide according to Claim 12.

18. The antibody of Claim 17 wherein said antibody is a monoclonal antibody.

19. The antibody of Claim 17 wherein said antibody is a humanized antibody.

20. The antibody of Claim 17 wherein said antibody is an antibody fragment.

21. An isolated nucleic acid which has at least 80% nucleic acid sequence identity to a nucleic acid sequence selected from the group consisting of that shown in Figure 1 (SEQ ID NO:3), Figure 3 (SEQ ID NO:5), Figure 5 (SEQ ID NO:7), Figure 7 (SEQ ID NO:9), Figure 9 (SEQ ID NO:11), Figure 11 (SEQ ID NO:16), Figure 13 (SEQ ID NO:21), Figure 15 (SEQ ID NO:23), Figure 17 (SEQ ID NO:28), Figure 19 (SEQ ID NO:30), Figure 21 (SEQ ID NO:32), Figure 23 (SEQ ID NO:40), Figure 25 (SEQ ID NO:42), Figure 27 (SEQ ID NO:49), Figure 29 (SEQ ID NO:51), Figure 31 (SEQ ID NO:53), Figure 33 (SEQ ID NO:55), Figure 35 (SEQ ID NO:57), Figure 37 (SEQ ID NO:62), Figure 39 (SEQ ID NO:67), Figure 41 (SEQ ID NO:69), Figure 43 (SEQ ID NO:71), Figure 45 (SEQ ID NO:76), Figure 47 (SEQ ID NO:78), Figure 49 (SEQ ID

NO:83), Figure 51 (SEQ ID NO:85), Figure 53 (SEQ ID NO:87), Figure 55 (SEQ ID NO:94), Figure 57 (SEQ ID NO:99), Figure 59 (SEQ ID NO:101), Figure 61 (SEQ ID NO:103), Figure 63 (SEQ ID NO:110), Figure 65 (SEQ ID NO:115), Figure 67 (SEQ ID NO:117), Figure 69 (SEQ ID NO:122), Figure 71 (SEQ ID NO:127), Figure 73 (SEQ ID NO:129), Figure 75 (SEQ ID NO:131), Figure 77 (SEQ ID NO:133), Figure 79 (SEQ ID NO:135), Figure 81 (SEQ ID NO:137), Figure 83 (SEQ ID NO:139), Figure 85 (SEQ ID NO:141), Figure 87 (SEQ ID NO:143), Figure 89 (SEQ ID NO:145), Figure 91 (SEQ ID NO:147), Figure 93 (SEQ ID NO:152), Figure 95 (SEQ ID NO:157), Figure 97 (SEQ ID NO:159), Figure 99 (SEQ ID NO:161), Figure 101 (SEQ ID NO:169), Figure 103 (SEQ ID NO:179), Figure 105 (SEQ ID NO:188), Figure 107 (SEQ ID NO:193), Figure 109 (SEQ ID NO:195), Figure 111 (SEQ ID NO:197), Figure 113 (SEQ ID NO:202), Figure 115 (SEQ ID NO:209), Figure 117 (SEQ ID NO:211), Figure 119 (SEQ ID NO:213), Figure 121 (SEQ ID NO:215), Figure 123 (SEQ ID NO:217), Figure 125 (SEQ ID NO:219), Figure 127 (SEQ ID NO:224), Figure 129 (SEQ ID NO:226), Figure 131 (SEQ ID NO:228), Figure 133 (SEQ ID NO:233), Figure 135 (SEQ ID NO:235), Figure 137 (SEQ ID NO:242), Figure 139 (SEQ ID NO:247), Figure 141 (SEQ ID NO:252), Figure 143 (SEQ ID NO:259), Figure 145 (SEQ ID NO:264), Figure 147 (SEQ ID NO:266), Figure 149 (SEQ ID NO:268), Figure 151 (SEQ ID NO:270), Figure 153 (SEQ ID NO:272), Figure 155 (SEQ ID NO:274), Figure 157 (SEQ ID NO:276), Figure 159 (SEQ ID NO:281), Figure 161 (SEQ ID NO:286), Figure 163 (SEQ ID NO:291), Figure 165 (SEQ ID NO:296), Figure 167 (SEQ ID NO:301), Figure 169 (SEQ ID NO:303), Figure 171 (SEQ ID NO:305), Figure 173 (SEQ ID NO:307), Figure 175 (SEQ ID NO:309), Figure 177 (SEQ ID NO:314), Figure 179 (SEQ ID NO:316), Figure 181 (SEQ ID NO:321), Figure 183 (SEQ ID NO:323), Figure 185 (SEQ ID NO:325), Figure 187 (SEQ ID NO:327), Figure 189 (SEQ ID NO:329), Figure 191 (SEQ ID NO:331), Figure 193 (SEQ ID NO:333), Figure 195 (SEQ ID NO:335), Figure 197 (SEQ ID NO:337), Figure 199 (SEQ ID NO:339), Figure 201 (SEQ ID NO:346), Figure 203 (SEQ ID NO:351), Figure 205 (SEQ ID NO:353), Figure 207 (SEQ ID NO:355), Figure 209 (SEQ ID NO:357), Figure 211 (SEQ ID NO:363), Figure 213 (SEQ ID NO:365), Figure 215 (SEQ ID NO:371), Figure 217 (SEQ ID NO:373), Figure 219 (SEQ ID NO:375), Figure 221 (SEQ ID NO:377), Figure 223 (SEQ ID NO:382), Figure 225 (SEQ ID NO:384), Figure 227 (SEQ ID NO:389), Figure 229 (SEQ ID NO:394), Figure 231 (SEQ ID NO:396), Figure 233 (SEQ ID NO:401), Figure 235 (SEQ ID NO:405), Figure 237 (SEQ ID NO:409), Figure 239 (SEQ ID NO:414), Figure 241 (SEQ ID NO:422), Figure 242 (SEQ ID NO:428) and Figure 245 (SEQ ID NO:430).

22. An isolated nucleic acid which has at least 80% nucleic acid sequence identity to the full-length coding sequence of a nucleotide sequence selected from the group consisting of that shown in Figure 1 (SEQ ID NO:3), Figure 3 (SEQ ID NO:5), Figure 5 (SEQ ID NO:7), Figure 7 (SEQ ID NO:9), Figure 9 (SEQ ID NO:11), Figure 11 (SEQ ID NO:16), Figure 13 (SEQ ID NO:21), Figure 15 (SEQ ID NO:23), Figure 17 (SEQ ID NO:28), Figure 19 (SEQ ID NO:30), Figure 21 (SEQ ID NO:32), Figure 23 (SEQ ID NO:40), Figure 25 (SEQ ID NO:42), Figure 27 (SEQ ID NO:49), Figure 29 (SEQ ID NO:51), Figure 31 (SEQ ID NO:53), Figure 33 (SEQ ID NO:55), Figure 35 (SEQ ID NO:57), Figure 37 (SEQ ID NO:62), Figure 39 (SEQ ID NO:67), Figure 41 (SEQ ID NO:69), Figure 43 (SEQ ID NO:71), Figure 45 (SEQ ID NO:76), Figure 47 (SEQ ID NO:78), Figure 49 (SEQ ID NO:83), Figure 51 (SEQ ID NO:85), Figure 53 (SEQ ID NO:87), Figure 55 (SEQ ID NO:94), Figure 57 (SEQ ID NO:99), Figure 59 (SEQ ID NO:101), Figure 61 (SEQ ID NO:103), Figure 63 (SEQ ID NO:110), Figure 65 (SEQ ID NO:115), Figure 67 (SEQ ID NO:117), Figure 69 (SEQ ID NO:122),

Figure 71 (SEQ ID NO:127), Figure 73 (SEQ ID NO:129), Figure 75 (SEQ ID NO:131), Figure 77 (SEQ ID NO:133), Figure 79 (SEQ ID NO:135), Figure 81 (SEQ ID NO:137), Figure 83 (SEQ ID NO:139), Figure 85 (SEQ ID NO:141), Figure 87 (SEQ ID NO:143), Figure 89 (SEQ ID NO:145), Figure 91 (SEQ ID NO:147), Figure 93 (SEQ ID NO:152), Figure 95 (SEQ ID NO:157), Figure 97 (SEQ ID NO:159), Figure 99 (SEQ ID NO:161), Figure 101 (SEQ ID NO:169), Figure 103 (SEQ ID NO:179), Figure 105 (SEQ ID NO:188), Figure 107 (SEQ ID NO:193), Figure 109 (SEQ ID NO:195), Figure 111 (SEQ ID NO:197), Figure 113 (SEQ ID NO:202), Figure 115 (SEQ ID NO:209), Figure 117 (SEQ ID NO:211), Figure 119 (SEQ ID NO:213), Figure 121 (SEQ ID NO:215), Figure 123 (SEQ ID NO:217), Figure 125 (SEQ ID NO:219), Figure 127 (SEQ ID NO:224), Figure 129 (SEQ ID NO:226), Figure 131 (SEQ ID NO:228), Figure 133 (SEQ ID NO:233), Figure 135 (SEQ ID NO:235), Figure 137 (SEQ ID NO:242), Figure 139 (SEQ ID NO:247), Figure 141 (SEQ ID NO:252), Figure 143 (SEQ ID NO:259), Figure 145 (SEQ ID NO:264), Figure 147 (SEQ ID NO:266), Figure 149 (SEQ ID NO:268), Figure 151 (SEQ ID NO:270), Figure 153 (SEQ ID NO:272), Figure 155 (SEQ ID NO:274), Figure 157 (SEQ ID NO:276), Figure 159 (SEQ ID NO:281), Figure 161 (SEQ ID NO:286), Figure 163 (SEQ ID NO:291), Figure 165 (SEQ ID NO:296), Figure 167 (SEQ ID NO:301), Figure 169 (SEQ ID NO:303), Figure 171 (SEQ ID NO:305), Figure 173 (SEQ ID NO:307), Figure 175 (SEQ ID NO:309), Figure 177 (SEQ ID NO:314), Figure 179 (SEQ ID NO:316), Figure 181 (SEQ ID NO:321), Figure 183 (SEQ ID NO:323), Figure 185 (SEQ ID NO:325), Figure 187 (SEQ ID NO:327), Figure 189 (SEQ ID NO:329), Figure 191 (SEQ ID NO:331), Figure 193 (SEQ ID NO:333), Figure 195 (SEQ ID NO:335), Figure 197 (SEQ ID NO:337), Figure 199 (SEQ ID NO:339), Figure 201 (SEQ ID NO:346), Figure 203 (SEQ ID NO:351), Figure 205 (SEQ ID NO:353), Figure 207 (SEQ ID NO:355), Figure 209 (SEQ ID NO:357), Figure 211 (SEQ ID NO:363), Figure 213 (SEQ ID NO:365), Figure 215 (SEQ ID NO:371), Figure 217 (SEQ ID NO:373), Figure 219 (SEQ ID NO:375), Figure 221 (SEQ ID NO:377), Figure 223 (SEQ ID NO:382), Figure 225 (SEQ ID NO:384), Figure 227 (SEQ ID NO:389), Figure 229 (SEQ ID NO:394), Figure 231 (SEQ ID NO:396), Figure 233 (SEQ ID NO:401), Figure 235 (SEQ ID NO:405), Figure 237 (SEQ ID NO:409), Figure 239 (SEQ ID NO:414), Figure 241 (SEQ ID NO:422), Figure 242 (SEQ ID NO:428) and Figure 245 (SEQ ID NO:430).

23. An isolated extracellular domain of a PRO polypeptide.

24. An isolated PRO polypeptide lacking its associated signal peptide.

25. An isolated polypeptide having at least about 80% amino acid sequence identity to an extracellular domain of of PRO polypeptide.

26. An isolated polypeptide having at least about 80% amino acid sequence identity to a PRO polypeptide lacking its associated signal peptide.

27. An isolated nucleic acid encoding the polypeptide of any one of Claims 23 to 26.